Journal of Clinical Oncology, Vol 1, 317-325, Copyright © 1983 by American Society of Clinical Oncology

ARTICLES

Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen

WA Bleyer, PF Coccia, HN Sather, C Level, J Lukens, DJ Niebrugge, S Siegel, PS Littman, SL Leikin and DR Miller

During the period 1976-1981, 3241 children were enrolled on three major studies of acute lymphoblastic leukemia by participating institutions of the Children's Cancer Study Group. Each study included a different method of central nervous system (CNS) prophylaxis: (1) standard therapy with cranial irradiation, 2400 rads, and intrathecal methotrexate at 12 mg/m2 six times during consolidation (CCG-141); (2) a modification of CCG-141 in which the intrathecal methotrexate was initiated during induction (CCG-141A); and (3) a reduced cranial irradiation dose of 1800 rads with intrathecal methotrexate given at the same frequency as a CCG-141A, with or without maintenance intrathecal methotrexate, but with a dosage regimen derived from CNS volume considerations rather than based on body surface area (CCG-160 series). Strategy 3, a change in the intrathecal methotrexate dosage, has resulted in the lowest incidence of CNS leukemia to date (p less than 0.007). The cumulative 3-yr CNS relapse rate has decreased from 8%- 10% to 2%-5% in average-risk patients (p less than 0.02; life table estimate) and from 23%-27% to 6% in high-risk patients (p less than 0.0002; life table estimate), despite a reduction in the cranial irradiation dose from 2400 to 1800 rads. Maintenance intrathecal chemotherapy has had a marginal effect among patients randomized to receive this additional therapy (p = 0.06). The overall outcome has been an increase in the continuous complete remission rate (p = 0.04) but not in the estimated 3-yr continuous hematologic remission or survival rates.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. S. Kadan-Lottick, P. Brouwers, D. Breiger, T. Kaleita, J. Dziura, V. Northrup, L. Chen, M. Nicoletti, B. Bostrom, L. Stork, et al. Comparison of Neurocognitive Functioning in Children Previously Randomly Assigned to Intrathecal Methotrexate Compared With Triple Intrathecal Therapy for the Treatment of Childhood Acute Lymphoblastic Leukemia J. Clin. Oncol., December 10, 2009; 27(35): 5986 - 5992. [Abstract] [Full Text] [PDF]

				M. L de Lemos, S. Monfared, T. Denyssevych, L. Hamata, S. Jennings, B. Thiessen, S. Smith, and D. Waterhouse Evaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringer's solution for intrathecal administration Journal of Oncology Pharmacy Practice, March 1, 2009; 15(1): 45 - 52. [Abstract] [PDF]

				E. Jabbour, S. O'Brien, H. Kantarjian, G. Garcia-Manero, A. Ferrajoli, F. Ravandi, M. Cabanillas, and D. A. Thomas Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia Blood, April 15, 2007; 109(8): 3214 - 3218. [Abstract] [Full Text] [PDF]

				Y. Matloub, S. Lindemulder, P. S. Gaynon, H. Sather, M. La, E. Broxson, R. Yanofsky, R. Hutchinson, N. A. Heerema, J. Nachman, et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group Blood, August 15, 2006; 108(4): 1165 - 1173. [Abstract] [Full Text] [PDF]

				G. Velez, P. Yuan, C. Sung, G. Tansey, G. F. Reed, C.-C. Chan, R. B. Nussenblatt, and M. R. Robinson Pharmacokinetics and Toxicity of Intravitreal Chemotherapy for Primary Intraocular Lymphoma Arch Ophthalmol, October 1, 2001; 119(10): 1518 - 1524. [Abstract] [Full Text] [PDF]

				S. L. Berg and D. G. Poplack Treatment of Meningeal Malignancy Oncologist, February 1, 1996; 1(1): 56 - 61. [Abstract] [Full Text] [PDF]

				H. H. Mahmoud, G. K. Rivera, M. L. Hancock, R. A. Krance, L. E. Kun, F. G. Behm, R. C. Ribeiro, J. T. Sandlund, W. M. Crist, and C.-H. Pui Low Leukocyte Counts with Blast Cells in Cerebrospinal Fluid of Children with Newly Diagnosed Acute Lymphoblastic Leukemia N. Engl. J. Med., July 29, 1993; 329(5): 314 - 319. [Abstract] [Full Text]